Loading…
Inhibikase Therapeutics, Inc. is projected to rise to $2.83 by 2027, a +30% move from its current price of $2.18. IKT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $2.12 | $2.18 | $2.24 | +0.03% |
| Aug 4 | $2.10 | $2.18 | $2.27 | +0.07% |
| Aug 5 | $2.08 | $2.18 | $2.29 | +0.10% |
| Aug 6 | $2.06 | $2.18 | $2.31 | +0.13% |
| Aug 7 | $2.05 | $2.18 | $2.33 | +0.16% |
| Aug 8 | $2.04 | $2.18 | $2.34 | +0.20% |
| Aug 9 | $2.03 | $2.18 | $2.35 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.03 | $2.18 | $2.35 | +0.23% |
| Week 2 | $1.97 | $2.19 | $2.43 | +0.46% |
| Week 3 | $1.93 | $2.19 | $2.50 | +0.69% |
| Week 4 | $1.89 | $2.20 | $2.55 | +0.92% |
| Week 5 | $1.87 | $2.21 | $2.61 | +1.15% |
| Week 6 | $1.84 | $2.21 | $2.65 | +1.38% |
| Week 7 | $1.82 | $2.22 | $2.70 | +1.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH). The company offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of PAH, intended to reduce areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.
IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. The company entered into a collaborative research and development agreement for prodrug technology development, maintains an exclusive license for IKT-001, and the collaboration was assigned to Pivot Holding LLC. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IKT is a Healthcare asset trading under the symbol IKT. The current price is $2.23 and the market cap stands at $350.18M, with a rank of 3155.
A major floor 28.0% below — a decisive break under it would weaken the trend.
The nearest floor, 16.1% below — buyers have tended to step in here.
The nearest ceiling, 7.8% above — a clean break opens room to run.
A major ceiling 21.1% above — clearing it would confirm fresh momentum.
Key IKT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IKT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.27 | Sell | $2.24 | Sell |
| MA 10 | $2.26 | Sell | $2.23 | Sell |
| MA 20 | $2.15 | Buy | $2.15 | Buy |
| MA 50 | $1.92 | Buy | $2.01 | Buy |
| MA 100 | $1.87 | Buy | $1.91 | Buy |
| MA 200 | $1.77 | Buy | $1.85 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.97 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 17.86 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | 5.83 | Buy |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | 0.80 | Buy |
| Awesome (5,34) | 0.24 | Buy |
| Ultimate (7,14,28) | 55.66 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 2.23 | Sell |
| ADX (14) | 29.04 | Buy |
| ATR (14) | 0.06 | Info |
The 30-day technical picture shows bullish sentiment with RSI(14) at 70, indicating strong momentum near overbought levels. The stock trades with a 30-day range of $1.86 to $2.67, and faces resistance at $2.23 while finding support at $1.62. The SMA50 is $1.84 and the SMA200 is $1.74, suggesting a positive short-term trend amid notable volatility (annualized volatility % of 50).
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.50 | $2.18 | $2.81 | 0% | Neutral | |
| $2.25 | $2.83 | $3.77 | +30% | Bullish | |
| $2.52 | $3.26 | $4.51 | +50% | Bullish | |
| $3.17 | $4.20 | $5.99 | +93% | Bullish | |
| $4.02 | $5.45 | $7.96 | +150% | Bullish | |
| $4.10 | $5.67 | $8.47 | +160% | Bullish | |
| $4.32 | $6.08 | $9.27 | +179% | Bullish | |
| $4.79 | $6.85 | $10.63 | +214% | Bullish | |
| $5.04 | $7.32 | $11.55 | +236% | Bullish | |
| $6.28 | $9.27 | $14.85 | +325% | Bullish | |
| $8.50 | $13.46 | $22.97 | +518% | Bullish | |
| $18.94 | $33.86 | $63.33 | +14.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.50 | $2.18 | $2.55 | +0.00% |
| September 2026 | $1.84 | $2.18 | $2.65 | -0.09% |
| October 2026 | $1.88 | $2.25 | $2.77 | +3.11% |
| November 2026 | $1.85 | $2.22 | $2.76 | -1.00% |
| December 2026 | $1.86 | $2.25 | $2.81 | +1.04% |
Click any year to see its month-by-month IKT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect IKT to range from $1.50 to $2.81 through 2026. The $2.18 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The IKT price prediction for 2027 points to an average of $2.83 (low $2.25, high $3.77) — a potential gain of +30% on today's $2.18. Momentum favours further upside here.
In 2028, IKT is projected to trade between $2.52 and $4.51, averaging $3.26 — a potential gain of +50% from today's $2.18. That is up +15% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Inhibikase Therapeutics, Inc.'s 2029 outlook centres on $4.20, within a $3.17 to $5.99 range. That is up +29% on the projected 2028 average. That marks a +93% change versus current levels. Momentum favours further upside here.
By 2030, IKT could reach as high as $7.96, with a base case around $5.45 and support toward $4.02 — roughly +150% from $2.18. Buyers look set to stay in control over this stretch.
Expect IKT to range from $4.10 to $8.47 through 2031. The $5.67 average target implies a +160% move from current prices. That is up +4% on the projected 2030 average. Momentum favours further upside here.
The IKT price prediction for 2032 points to an average of $6.08 (low $4.32, high $9.27) — a potential gain of +179% on today's $2.18. Buyers look set to stay in control over this stretch.
In 2033, IKT is projected to trade between $4.79 and $10.63, averaging $6.85 — a potential gain of +214% from today's $2.18. That is up +13% on the projected 2032 average. Momentum favours further upside here.
Inhibikase Therapeutics, Inc.'s 2034 outlook centres on $7.32, within a $5.04 to $11.55 range. That is up +7% on the projected 2033 average. That marks a +236% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, IKT could reach as high as $14.85, with a base case around $9.27 and support toward $6.28 — roughly +325% from $2.18. Momentum favours further upside here.
Expect IKT to range from $8.50 to $22.97 through 2040. The $13.46 average target implies a +518% move from current prices. That is up +45% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The IKT price prediction for 2050 points to an average of $33.86 (low $18.94, high $63.33) — a potential gain of +14.5x on today's $2.18. Momentum favours further upside here.
Investing $1,000 in IKT today (≈ 458.715596 IKT) could be worth
$15,533.6
+$14,533.6 (+1453%) by 2050 · US Dollar
Based on the average projected IKT price of $33.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IKTwould be worth at today's price.
$1,000 invested in IKT on Jul 31, 2025 (≈ 632.911375 IKT) would be worth
$1,379.75
+$379.75 (+38.0%) today · 1.38× · US Dollar
Based on a IKT entry price of $1.58 vs. today's $2.18.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.33 | $935.62 | -6.4% |
| 1 month ago | $1.94 | $1,123.71 | +12.4% |
| 3 months ago | $1.91 | $1,141.36 | +14.1% |
| 6 months ago | $1.57 | $1,388.53 | +38.9% |
| 1 year ago | $1.58 | $1,379.75 | +38.0% |
| All time (5.0y) ago | $13.2 | $165.15 | -83.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IKT forecast.
Our base-case forecast reaches $4.40 around 2030.
Implied market cap at $4.40: $690.94M
The multi-year forecast envisions an overall upside path. In 2026 the average price is $2.23 (min $1.50, max $2.91) with a 0% ROI and neutral sentiment. From 2027 onward, forecasts turn bullish, with the average price rising to $2.82 in 2027 (max $3.74, min $2.25) and an ROI of 26.4%.
The averages continue higher each year, with 2030 at $5.21 (ROI 133.7%), 2035 at $8.48 (ROI 280.4%), 2040 at $11.82 (ROI 429.9%), and 2050 at $29.63 (ROI 1228.9%), all labeled bullish. The implied max prices rise to $7.56 by 2030 and reach $54.65 by 2050, underscoring a long-run bullish trajectory while acknowledging these are estimates, not guarantees, and subject to risk and uncertainty.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $5.21 with a minimum of $3.87 and a maximum of $7.56, and an implied ROI of 133.7% with bullish sentiment.
Forecasts indicate a bullish path beyond 2026, with the average price increasing to $29.63 by 2050 and a maximum of $54.65, delivering an implied ROI of up to 1228.9%. Note that 2026 is neutral with an average of $2.23 and 0% ROI, and these figures are estimates, not guarantees.
Yes. The forecast shows a maximum of $10.46 in 2034 and $13.45 in 2035, indicating the asset could surpass $10 in the mid-2030s.
The current price is $2.23 and the market cap is $350.18M.
The 30-day picture is bullish with RSI(14) at 70. The price trades near resistance at $2.23 and has support at $1.62, with a 30-day range of $1.86 to $2.67 and annualized volatility of 50%.
Inhibikase Therapeutics, Inc. Community Discussion
0Share your Inhibikase Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.